Product nameAnti-EpCAM antibody [VU-1D9] (PerCP/Cy5.5®)
See all EpCAM primary antibodies
DescriptionMouse monoclonal [VU-1D9] to EpCAM (PerCP/Cy5.5®)
ConjugationPerCP/Cy5.5®. Ex: 482nm, Em: 690nm
Specificityab157319 recognizes an epitope within EGF-like domain I of EpCAM, a marker of epithelial lineages. This antibody strongly stains various normal epithelial cells and carcinomas.
Tested applicationsSuitable for: Flow Cyt, IHC-P, IP, WB, IHC-Fr, ICCmore details
Species reactivityReacts with: Human
Small cell lung carcinoma cell line H69.
- Recombinant Human EpCAM protein (ab131790) can be used as a positive control in WB. Colon epithelium
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferPreservative: 0.1% Sodium azide
Constituents: 99% PBS, 0.2% BSA
BSA is high-grade, protease free.
Concentration information loading...
Purification notesab157319 is conjugated with tandem dye PerCP-Cy™5.5 under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
- Anti-EpCAM antibody [VU-1D9] (FITC) (ab112067)
- Anti-EpCAM antibody [VU-1D9] (Phycoerythrin) (ab112068)
- Anti-EpCAM antibody [VU-1D9] (ab187372)
- Anti-EpCAM antibody [VU-1D9] - BSA and Azide free (ab212579)
- Anti-EpCAM antibody [VU-1D9] (Alexa Fluor® 647) (ab239273)
- Anti-EpCAM antibody [VU-1D9] (Allophycocyanin) (ab239288)
- Anti-EpCAM antibody [VU-1D9] (Biotin) (ab79079)
Our Abpromise guarantee covers the use of ab157319 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use 4µl for 106 cells.
Also 4 µl per 100 µl whole blood.
ab157226 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
|IHC-P||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration. Predicted molecular weight: 35 kDa.|
|IHC-Fr||Use at an assay dependent concentration.|
|ICC||Use at an assay dependent concentration.|
FunctionMay act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. Up-regulates the expression of FABP5, MYC and cyclins A and E.
Tissue specificityHighly and selectively expressed by undifferentiated rather than differentiated embryonic stem cells (ESC). Levels rapidly diminish as soon as ESC's differentiate (at protein levels). Expressed in almost all epithelial cell membranes but not on mesodermal or neural cell membranes. Found on the surface of adenocarcinoma.
Involvement in diseaseDefects in EPCAM are the cause of diarrhea type 5 (DIAR5) [MIM:613217]. It is an intractable diarrhea of infancy characterized by villous atrophy and absence of inflammation, with intestinal epithelial cell dysplasia manifesting as focal epithelial tufts in the duodenum and jejunum.
Defects in EPCAM are a cause of hereditary non-polyposis colorectal cancer type 8 (HNPCC8) [MIM:613244]. HNPCC is a disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. Note=HNPCC8 results from heterozygous deletion of 3-prime exons of EPCAM and intergenic regions directly upstream of MSH2, resulting in transcriptional read-through and epigenetic silencing of MSH2 in tissues expressing EPCAM.
Sequence similaritiesBelongs to the EPCAM family.
Contains 1 thyroglobulin type-1 domain.
modificationsHyperglycosylated in carcinoma tissue as compared with autologous normal epithelia. Glycosylation at Asn-198 is crucial for protein stability.
Cellular localizationLateral cell membrane. Cell junction > tight junction. Co-localizes with CLDN7 at the lateral cell membrane and tight junction.
- Information by UniProt
- 17 1A antibody
- 323/A3 antibody
- Adenocarcinoma associated antigen antibody
This product has been referenced in:
- Pedrol E et al. Optofluidic device for the quantification of circulating tumor cells in breast cancer. Sci Rep 7:3677 (2017). IHC-P ; Mouse . Read more (PubMed: 28623262) »
- Holton AB et al. Microfluidic Biopsy Trapping Device for the Real-Time Monitoring of Tumor Microenvironment. PLoS One 12:e0169797 (2017). Read more (PubMed: 28085924) »